Colorectal cancer: Current care, future innovations and economic considerations

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 6, Issue 2, 2006, Pages 195-206

  Macafee, David A L ^a   Gemmill, Elizabeth H ^b   Lund, John N ^a  

^a DERBY CITY GENERAL HOSPITAL   (United Kingdom)

^b JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

Cancer; Colorectal; Cost; Follow up; Hospital; Palliation; Resources; Screening

Indexed keywords

ACETYLSALICYLIC ACID; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPECITABINE; CYCLOOXYGENASE 2; FLUOROURACIL; FOLINATE CALCIUM; FOLINIC ACID; IRINOTECAN; MINICHROMOSOME MAINTENANCE PROTEIN; MINICHROMOSOME MAINTENANCE PROTEIN 2; NONSTEROID ANTIINFLAMMATORY AGENT; OXALIPLATIN; UFT;

ADVANCED CANCER; CANCER ADJUVANT THERAPY; CANCER INCIDENCE; CANCER PALLIATIVE THERAPY; CANCER RECURRENCE; CANCER SCREENING; CANCER STAGING; CLINICAL TRIAL; COLONOSCOPY; COLORECTAL CANCER; COMPUTED TOMOGRAPHIC COLONOGRAPHY; COST UTILITY ANALYSIS; EARLY DIAGNOSIS; ELDERLY CARE; FATIGUE; HEALTH ECONOMICS; HOME CARE; HUMAN; LAPAROSCOPIC SURGERY; LIVER METASTASIS; LUNG METASTASIS; MASS SCREENING; META ANALYSIS; MINIMALLY INVASIVE SURGERY; MULTIMODALITY CANCER THERAPY; NON INVASIVE PROCEDURE; PREOPERATIVE CARE; PROTEOMICS; REVIEW; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; UNITED KINGDOM;

EID: 33646100529     PISSN: 14737167     EISSN: 17448379     Source Type: Journal    
DOI: 10.1586/14737167.6.2.195     Document Type: Review

References (85)

1. Cancer Research UK. British cancer death rates. Br. Med. J. 328, 303 (2004).
2. Maxwell-Armstrong CA, Scholefield JH. Colorectal cancer. In: Clinical Evidence (Volume 10). Godlee F (Ed.). BMJ Publishing group, London, UK 509-517 (2003).
3. Bingham SA, Day NE, Luben R et al. Dietary fibre in food and protection against colorectal cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC): an observational study. Lancet 361(9368), 1496-1501 (2003).
4. Leslie A, Carey FA, Pratt NR, Steele RJC. The colorectal adenoma-carcinoma sequence. Br. J. Surg. 89, 845-860 (2002).
5. Smith JJ, Lee J, Burke C, Contractor KB, Dawson PM. Major colorectal cancer resection should not be denied to the elderly. Eur. J. Surg. Oncol. 28, 661-666 (2002).
6. Cancer Line UK. Colorectal cancer. In: Cancer line UK (2003).
7. Minsky BD. Multidisciplinary case teams: an approach to the future management of advanced colorectal cancer. Br. J. Cancer 77(Suppl. 2), 1-4 (1998).
8. Macafee DAL. The cost of screening and caring for patients with colorectal cancer. Nottingham (2005).
9. Northover J. Follow-up after curative surgery for colorectal cancer. The Association of Coloproctology of Great Britain and Ireland. London, UK (2003).
10. Lund JN, Scholefield JH, Grainge MJ et al. Risks, costs and compliance limit colorectal adenoma surveillance: lessons from a randomised trial. Gut 49, 91-96 (2001).
11. Memon MA, Beckingham, IJ. Surgical resection of colorectal liver metastases. Colorectal Dis. 3(6), 361-372 (2001).
12. Beard SM, Holmes M, Price C, Majeed AW. Hepatic resection for colorectal liver metastases: a cost-effectiveness analysis. Ann. Surg. 232(6), 763-776 (2000).
13. Khatri VP, Petrelli NJ, Belghiti J. Extending the frontiers of surgical therapy for hepatic colorectal metastases: is there a limit? J. Clin. Oncol. 23(33), 8490-8499 (2005).
14. Colorectal Cancer Collaborative Group. Palliative chemotherapy for advanced colorectal cancer. Br. Med. J. 321, 531-535 (2000).
15. Nolte W, Ramadori G. Recent aspects of palliative treatment of metastasised colorectal carcinoma. Med. Clin. (Munich) 96(9), 521-528 (2001).
16. Coyle D, Small N, Ashworth A et al. Costs of palliative care in the community, in hospitals and in hospices in the UK. Crit. Rev. Oncol. Hematol. 32, 71-85 (1999).
17. World Health Organization. World Cancer Report. New York, USA (2003).
18. Regueiro CR, AGA Future Trends Committee. AGA Future Trends Committee Report: colorectal cancer: a qualitative review of emerging screening and diagnostic technologies. Gastroenterology 129, 1083-1103 (2005).
19. Whynes DK, Neilson AR, Robinson MHE, Hardcastle JD. Colorectal cancer screening and quality of life. Qual. Life Res. 3(3), 191-198 (1994).
20. Doorbar J, Cubie H. Molecular basis for advances in cervical screening. Mol. Diagn. 9(3), 129-142 (2005).
21. Muir KR, Logan RFA. Aspirin, NSAIDs and colorectal cancer-what do the epidemiological studies show and what do they tell us about the modus operandi? Apoptosis 4(5), 389-396 (1999).
22. Sandler RS, Halabi S, Baron JA et al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N. Engl. J. Med. 10(348), 883-890 (2003).
23. Subramanian S, Klosterman M, Amonkar MM, Hunt TL. Adherence with colorectal cancer screening guidelines: a review. Preventive Medicine 38, 536-550 (2004).
24. Smith RA, Cokkinides V, Eyre HJ. American cancer society guidelines for the early detection of cancer 2004. CA Cancer J. Clin. 54, 41-52 (2004).
25. Garvican L. Planning for a possible national colorectal cancer screening programme. J. Med. Screen. 5(4), 187-194 (1998).
26. Robert G, Brown J, Garvican L. Cost of quality management and information provision for screening: colorectal cancer screening. J. Med. Screen. 7(1), 31-34 (2000).
27. Towler BP, Irwig L, Glasziou P. Screening for colorectal cancer using the faecal occult blood test, haemoccult. Cochrane Database Syst. Rev. 2 (2000).
28. UK Flexible Sigmoidoscopy Screening Trial Investigators. Single flexible sigmoidoscopy screening to prevent colorectal cancer: baseline findings of a UK multicentre randomised trial. Lancet 359, 1291-1300 (2002).
29. Taylor SA, Halligan S, Saunders BP et al. Use of multidetector-row CT colonography for detection of colorectal neoplasia in patients referred via the Department of Health '2-week-wait' initiative. Clin. Radiol. 58, 855-861 (2003).
30. Bowles CJA, Leicester R, Romaya C, Swarbrick E, Williams CB, Epstein O. A prospective study of colonoscopy practice in the UK today: are we adequately prepared for national colorectal cancer screening tomorrow. Gut 53, 277-283 (2004).
31. Young GP, St John DJ, Winawer SJ, Rozen P, WHO (World Health Organization), OMED(World Organization for Digestive Endoscopy). Choice of fecal occult blood tests for colorectal cancer screening: recommendations based on performance characteristics in population studies: a WHO and OMED report. Am. J. Gastroenterol. 97(10), 2499-2507 (2002).
32. Whynes DK, Walker AR, Chamberlain JO, Hardcastle JD. Screening and the costs of treating colorectal cancer. Br. J. Cancer 68, 965-968 (1993).
33. Hardcastle JD, Balfour TW, Amar SS. Screening for symptomless colorectal cancer by testing for occult blood in General Practice. Lancet 1, 791-793 (1980).
34. Walker AR, Whynes DK. Participation and screening programmes for colorectal cancer: more would be better? J. Health Econ. 10, 207-225 (1991).
35. Schroy PC, Heeren TC. Patient perceptions of stool-based DNA testing for colorectal cancer screening. Am. J. Prevent. Med. 28(2), 208-214 (2005).
36. Ling BS, Moskowitz MA, Wachs D, Pearson B, Schroy PC. Attitudes toward colorectal cancer screening tests. J. Gen. Int. Med. 16(12), 822-830 (2001).
37. Robinson MHE, Hardcastle JD. Screening for Colorectal Cancer - Who, When and How. Oxford, Blackwell Science, UK (2000).
38. Feldman AL, Espina V, Petricoin EF, Liotta LA, Rosenblatt KP. Use of proteomic patterns to screen for gastrointestinal malignancies. Surgery 135(3), 243-247 (2004).
39. Wilson JF. The promise of disease proteomics: faster detection, diagnosis, and drug development. Ann. Intern. Med. 140(4), 317-319 (2004).
40. Brunagel G, Schoen RE, Getzenberg RH. Colon cancer specific nuclear matrix protein alterations in human colonic adenomatous polyps. J. Cell. Biochem. 91(2), 365-374 (2004).
41. Sirieix PS, O'Donovan M, Brown J, Save V, Coleman N, Fitzgerald RC. Surface expression of minichromosome maintenance proteins provides a novel method for detecting patients at risk for developing adenocarcinoma in Barrett's esophagus. Clin. Cancer Res. 9(7), 2560-2566 (2003).
42. Davies RJ, Freeman A, Morris LS et al. Analysis of minichromosome maintenance proteins as a novel method for detection of colorectal cancer in stool. Lancet 359(9321), 1917-1919 (2002).
43. Kanaoka S, Yoshida K, Miura N, Sugimura H, Kajimura M. Potential usefulness of detecting cyclooxygenase 2 messenger RNA in feces for colorectal cancer screening. Gastroenterology 127(2), 422-427 (2004).
44. Ouyang DL, Chen JJ, Getzenberg RH, Schoen RE. Noninvasive testing for colorectal cancer: a review. Am. J. Gastroenterol. 100(6), 1393-1403 (2005).
45. Dove-Edwin I, Sasieni P, Adams J, Thomas HJ. Prevention of colorectal cancer by colonoscopic surveillance in individuals with a family history of colorectal cancer: 16 year, prospective, follow-up study. Br. Med. J. 331(7524), 1047 (2005).
46. Pfau PR, Sivak MVJ. Endoscopic diagnostics. Gastroenterology 120(3), 763-781 (2001).
47. Taylor SA, Halligan S, O'Donnell C et al. Cardiovascular effects at multi-detector row CT colonography compared with those at conventional endoscopy of the colon. Radiology 229, 782-790 (2003).
48. White TJ, Avery GR, Kennan N, Syed A, Hartley JE, Monson JRT. Virtual versus conventional colonoscopy-patient preference and tolerability. Colorectal Dis. 6S1, 74 (2004).
49. Miao, YM, Amin Z, Healy J et al. A prospective single centre study comparing computed tomography pneumocolon against colonoscopy in the detection of colorectal neoplasms. Gut 47(6), 832-837 (2000).
50. Kahi CJ, Rex DK. Current and future trends in colorectal cancer screening. Cancer Metastasis Rev. 23, 137-144 (2004).
51. Rabaneck L. Is computed tomographic colonography effective for colorectal cancer screening. Can. Med. Ass. J. 170(9), 1392 (2004).
52. Cotton PB, Durkalski VL, Pineau BC et al. Computed tomographic colonography (virtual colonoscopy). A multicenter comparison with standard colonoscopy for detection of colorectal neoplasia. JAMA 291(14), 1713-1719 (2004).
53. Johnson CD, Harmsen WS, Wilson LA et al. Prospective blinded evaluation of computed tomographic colonography for screen detection of colorectal polyps. Gastroenterology 125(2), 311-319 (2003).
54. Ladabaum U, Song K. Projected national impact of colorectal cancer screening on clinical and economic outcomes and health services demand. Gastroenterology 129(4), 1151-1162 (2005).
55. Kim J, Czernin J, Allen-Auerbach M et al. Comparison between 18F-FDG PET, inline PET/CT, and software fusion for restaging of recurrent colorectal cancer. J. Nucl. Med. 46(4), 587-595 (2005).
56. Artiko V, Obradovic V, Davidovic B et al. Radioimmunodetection of colorectal carcinoma. Hepatogastroenterology 50(2), 1029-1031 (2003).
57. Thaler K, Kanneganti S, Khajanchee Y, Wilson C, Swanstrom L, Hansen P. The evolving role of staging laparoscopy in the treatment of colorectal hepatic metastasis. Arch. Surg. 140(8), 727-734 (2005).
58. Taplin SH, Barlow W, Urban N et al. Stage, age, comorbidity, and direct costs of colon, prostate, and breast cancer care. J. Natl Cancer Inst. 87(6), 417-426 (1995).
59. Whynes DK, Walker AR, Hardcastle JD. Cost-effective screening stratergies for colorectal cancer. J. Pub. Health Med. 14(1), 43-49 (1992).
60. Kehlet H, Wilmore DW. Multimodal stratergies to improve surgical outcome. Am. J. Surg. 183, 630-641 (2002).
61. Guillou P, Quirke P, Thorpe H et al. Shortterm endpoints of conventional versus laparoscopic-assisted surgery in patients with colorectal cancer (MRC CLASICC trial): multicentre, randomised controlled trial. Lancet 365(9472), 1718-1726 (2005).
62. Macafee DAL, Maxwell-Armstrong CA, Scholefield JH. Laparoscopic colorectal cancer surgery. Expert Rev. Anticancer Ther. 3(4), 484-492 (2003).
63. Camma C, Giunta M, Fiorica F, Pagliaro L, Craxi A, Cottone M. Preoperative radiotherapy for resectable rectal cancer: a meta-analysis. JAMA 284(8), 1008-1015 (2000).
64. Lidder PG, Hosie KB. Rectal cancer: the role of radiotherapy. Dig. Surg. 22(22), 41-48 (2005).
65. Van den Brink M, Van den Hout WB, Stigglebout AM et al. Cost-utility analysis of preoperative radiotherapy in patients with rectal cancer undergoing total mesorectal excision: a study of the dutch colorectal cancer group. J. Clin. Oncol. 22(2), 244-253 (2004).
66. Haydon A. Adjuvant chemotherapy in colon cancer: what is the evidence? Int. Med. J. 33(3), 119-124 (2003).
67. Twelves C, Boyer M, Findlay M et al. Capecitabine (Xeloda®) improves medical resource use compared with 5-fluorouracil plus leucovorin in a phase III trial conducted in patients with advanced colorectal carcinoma. Eur. J. Cancer 37(5), 597-604 (2001).
68. Marsh S. Pharmacogenetics of colorectal cancer. Expert Opin. Pharmacother. 6(15), 2607-2616 (2005).
69. Hale JP, Cohen DR, Maughan TS, Stephens RJ. Costs and consequences of different chemotherapy regimens in metastatic colorectal cancer. Br. J. Cancer 86, 1684-1690 (2002).
70. Norum J, Balteskard L, Edna TH, Lainc, R, Wahlby L, Ronning G. Ralitrexed or Nordic-FLv regimen in metastatic colorectal cancer: a randomized phase II study focussing on quality of life, patient's preference and health economics. J. Chemother. 14(3), 301-308 (2002).
71. Ward S, Kaltenthaler E, Cowan J. Brewer N. Clinical and cost-effectiveness of capecitabine and tegafur with uracil for the treatment of metastatic colorectal cancer: systematic review and economic evaluation. Health Tech. Assess. 7(32), 1-122 (2003).
72. Schilsky RL. First-line treatment options for patients with metastatic colorectal cancer. Nat. Clin. Pract. Oncol. 1(2), 70-71 (2004).
73. Bottomley A. Metastatic colorectal cancer: treatment challenges and quality of life. Lancet 359, 1537-1538 (2002).
74. Flechtner H, Bottomley A. Fatigue assessment in cancer clinical trials. Expert Rev. Pharmacoeconomics Outcomes Res. 2, 89-92 (2002).
75. Glimelius B, Hoffman K, Graf W. Cost-effectiveness of palliative chemotherapy in advanced gastrointestinal cancer. Ann. Oncol. 6, 267-274 (1995).
76. Evans L. Estimated basic costings of loop ileostomist stoma equipment needs. Paper. Derby, Derby City Hospital (2004).
77. British Society of Gastroenterology, Association of Coloproctology for Great Britain and Ireland, Scholefield JH, Steele RJC. Guidelines for follow up after resection of colorectal cancer. Gut 51, v3-v5 (2002).
78. Renehan AG, O'Dwyer PJ, Whynes DK. Cost effectiveness analysis of intensive versus conventional follow up after curative resection for colorectal cancer. Br. Med. J. 328, 81-84 (2004).
79. Korner H, Soreide K, Stokkeland PJ, Soreide JA. Systematic follow-up after curative surgery for colorectal cancer in Norway: a population-based audit of effectiveness, costs, and compliance. J. Gastrointest. Surg. 9(3), 320-328 (2005).
80. Secco GB, Fardelli R, Gianquinto D et al. Efficacy and cost of risk-adapted follow-up in patients after colorectal cancer surgery: a prospective, randomized and controlled trial. Eur. J. Surg. Oncol. 28(4), 418-423 (2002).
81. Oeppen J, Vaupel JW. Broken limits to life expectancy. Science 296, 1029-1031 (2002).
82. Ward S, Cowan J. Analysis of the potential cost impact of the guidance on cancer services: 'Improving outcomes in colorectal cancer' Expansion in endoscopy capacity - draft for 2nd consultation. Sheffield, School of Health and Related Research, University of Sheffield, UK (2003).
83. Sikora K, Bosanquet N. Cancer care in the United Kingdom: new solutions are needed. Br. Med, J. 327, 1044-1046 (2003).
84. Bismuth H, Adam R, Levi F et al. Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann. Surg. 224(4), 520-552 (1996).
85. Rozen P. Implementing colorectal cancer screening: group 2 report. Endoscopy 36, 354-358 (2004).